| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 89 | 2024 | 1851 | 6.080 |
Why?
|
| Gastrointestinal Stromal Tumors | 29 | 2023 | 318 | 5.210 |
Why?
|
| Soft Tissue Neoplasms | 39 | 2024 | 930 | 3.450 |
Why?
|
| Bone Neoplasms | 35 | 2023 | 2674 | 2.840 |
Why?
|
| Gastrointestinal Neoplasms | 21 | 2021 | 629 | 2.790 |
Why?
|
| Osteosarcoma | 27 | 2023 | 951 | 2.500 |
Why?
|
| Leiomyosarcoma | 12 | 2024 | 253 | 2.210 |
Why?
|
| Liposarcoma | 12 | 2024 | 248 | 2.110 |
Why?
|
| Antineoplastic Agents | 56 | 2021 | 14636 | 1.980 |
Why?
|
| Dacarbazine | 14 | 2021 | 502 | 1.890 |
Why?
|
| Dioxoles | 7 | 2017 | 23 | 1.850 |
Why?
|
| Tetrahydroisoquinolines | 7 | 2017 | 24 | 1.840 |
Why?
|
| Piperazines | 24 | 2014 | 2145 | 1.800 |
Why?
|
| Antineoplastic Agents, Alkylating | 12 | 2021 | 605 | 1.770 |
Why?
|
| Sarcoma, Ewing | 15 | 2020 | 428 | 1.760 |
Why?
|
| Pyrimidines | 29 | 2020 | 3671 | 1.600 |
Why?
|
| Sarcoma, Alveolar Soft Part | 7 | 2023 | 74 | 1.570 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 53 | 2022 | 16720 | 1.500 |
Why?
|
| Protein Kinase Inhibitors | 17 | 2023 | 4965 | 1.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 15 | 2021 | 485 | 0.990 |
Why?
|
| Benzamides | 24 | 2014 | 1879 | 0.990 |
Why?
|
| Chondrosarcoma | 9 | 2023 | 213 | 0.960 |
Why?
|
| Ifosfamide | 16 | 2017 | 358 | 0.920 |
Why?
|
| Imatinib Mesylate | 26 | 2018 | 1691 | 0.910 |
Why?
|
| Hemangiosarcoma | 5 | 2022 | 238 | 0.860 |
Why?
|
| Doxorubicin | 26 | 2021 | 3146 | 0.820 |
Why?
|
| Spinal Neoplasms | 10 | 2018 | 671 | 0.790 |
Why?
|
| Humans | 236 | 2024 | 271081 | 0.760 |
Why?
|
| Chordoma | 5 | 2024 | 170 | 0.730 |
Why?
|
| Adult | 136 | 2024 | 82171 | 0.710 |
Why?
|
| Ketones | 2 | 2017 | 57 | 0.690 |
Why?
|
| Furans | 2 | 2017 | 102 | 0.690 |
Why?
|
| Fibromatosis, Aggressive | 5 | 2022 | 110 | 0.680 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 6 | 2021 | 125 | 0.660 |
Why?
|
| Molecular Targeted Therapy | 9 | 2024 | 2395 | 0.650 |
Why?
|
| Aged | 111 | 2024 | 73545 | 0.640 |
Why?
|
| Deoxycytidine | 7 | 2020 | 1389 | 0.610 |
Why?
|
| Neoplasm Recurrence, Local | 36 | 2022 | 10400 | 0.610 |
Why?
|
| Disease-Free Survival | 40 | 2021 | 10267 | 0.600 |
Why?
|
| Treatment Outcome | 66 | 2021 | 33807 | 0.580 |
Why?
|
| Middle Aged | 124 | 2024 | 90521 | 0.570 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2016 | 5 | 0.560 |
Why?
|
| Combined Modality Therapy | 45 | 2020 | 9039 | 0.560 |
Why?
|
| Splenic Artery | 1 | 2017 | 54 | 0.550 |
Why?
|
| Intracranial Embolism | 1 | 2016 | 40 | 0.550 |
Why?
|
| Male | 134 | 2024 | 128479 | 0.540 |
Why?
|
| Drug Administration Schedule | 17 | 2021 | 3533 | 0.540 |
Why?
|
| Clinical Trials as Topic | 16 | 2021 | 3845 | 0.530 |
Why?
|
| Retroperitoneal Neoplasms | 6 | 2024 | 296 | 0.530 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2022 | 3416 | 0.520 |
Why?
|
| Sarcoma, Synovial | 7 | 2024 | 141 | 0.510 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2016 | 1270 | 0.490 |
Why?
|
| Embolization, Therapeutic | 3 | 2017 | 605 | 0.490 |
Why?
|
| Female | 131 | 2024 | 149115 | 0.480 |
Why?
|
| Adolescent | 72 | 2024 | 32783 | 0.470 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 342 | 0.460 |
Why?
|
| Survival Analysis | 22 | 2019 | 9290 | 0.440 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2013 | 40 | 0.430 |
Why?
|
| Prognosis | 36 | 2024 | 22529 | 0.420 |
Why?
|
| Preoperative Care | 4 | 2016 | 1580 | 0.410 |
Why?
|
| Young Adult | 41 | 2024 | 22293 | 0.400 |
Why?
|
| Survival Rate | 33 | 2024 | 12535 | 0.400 |
Why?
|
| Pyrroles | 5 | 2021 | 588 | 0.390 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2017 | 1536 | 0.390 |
Why?
|
| Neoadjuvant Therapy | 10 | 2024 | 5238 | 0.370 |
Why?
|
| Pyridines | 4 | 2021 | 1313 | 0.370 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2017 | 5055 | 0.370 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2022 | 1338 | 0.370 |
Why?
|
| Phenylurea Compounds | 3 | 2021 | 600 | 0.370 |
Why?
|
| Chemotherapy, Adjuvant | 18 | 2016 | 4006 | 0.350 |
Why?
|
| Camptothecin | 2 | 2003 | 540 | 0.350 |
Why?
|
| Aged, 80 and over | 49 | 2024 | 31078 | 0.350 |
Why?
|
| Medical Oncology | 2 | 2020 | 1463 | 0.340 |
Why?
|
| Kaplan-Meier Estimate | 18 | 2021 | 6258 | 0.340 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2011 | 347 | 0.340 |
Why?
|
| Retrospective Studies | 57 | 2024 | 39951 | 0.320 |
Why?
|
| Dasatinib | 3 | 2018 | 881 | 0.320 |
Why?
|
| Neoplasm Metastasis | 14 | 2016 | 5317 | 0.310 |
Why?
|
| Rhabdomyosarcoma | 6 | 2015 | 342 | 0.290 |
Why?
|
| Disease Progression | 15 | 2021 | 6868 | 0.290 |
Why?
|
| Paraganglioma | 3 | 2014 | 200 | 0.280 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 2 | 2018 | 88 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 5 | 2022 | 4481 | 0.270 |
Why?
|
| Infusions, Intravenous | 7 | 2017 | 1435 | 0.260 |
Why?
|
| Sulfonamides | 5 | 2020 | 1941 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 2050 | 0.260 |
Why?
|
| Testicular Neoplasms | 4 | 1990 | 560 | 0.260 |
Why?
|
| Giant Cell Tumor of Bone | 2 | 2016 | 53 | 0.250 |
Why?
|
| Pheochromocytoma | 3 | 2014 | 310 | 0.240 |
Why?
|
| Leukemia, Myeloid | 1 | 2009 | 993 | 0.240 |
Why?
|
| Ribonuclease H | 1 | 2024 | 18 | 0.240 |
Why?
|
| Clinical Decision-Making | 3 | 2016 | 536 | 0.240 |
Why?
|
| Follow-Up Studies | 24 | 2020 | 15281 | 0.240 |
Why?
|
| Neoplasm Staging | 20 | 2019 | 14020 | 0.240 |
Why?
|
| Oligopeptides | 1 | 2006 | 450 | 0.230 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2005 | 227 | 0.230 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2017 | 497 | 0.230 |
Why?
|
| Maximum Tolerated Dose | 6 | 2020 | 1329 | 0.230 |
Why?
|
| Leg | 3 | 2010 | 216 | 0.230 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2019 | 1347 | 0.230 |
Why?
|
| Neutropenia | 6 | 2020 | 1005 | 0.230 |
Why?
|
| Indoles | 4 | 2023 | 1029 | 0.220 |
Why?
|
| Triazines | 2 | 2021 | 121 | 0.220 |
Why?
|
| Solitary Fibrous Tumors | 2 | 2016 | 48 | 0.220 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 2015 | 1837 | 0.220 |
Why?
|
| Anthracyclines | 5 | 2020 | 339 | 0.220 |
Why?
|
| Adrenal Gland Neoplasms | 3 | 2014 | 527 | 0.220 |
Why?
|
| Giant Cell Tumor of Tendon Sheath | 1 | 2022 | 4 | 0.210 |
Why?
|
| Child | 33 | 2024 | 30596 | 0.210 |
Why?
|
| Risk Factors | 15 | 2016 | 17910 | 0.210 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2004 | 271 | 0.210 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2021 | 503 | 0.210 |
Why?
|
| Extremities | 6 | 2015 | 311 | 0.210 |
Why?
|
| Indazoles | 6 | 2020 | 310 | 0.200 |
Why?
|
| Salvage Therapy | 4 | 2017 | 2124 | 0.190 |
Why?
|
| Uterine Neoplasms | 2 | 2017 | 576 | 0.190 |
Why?
|
| Liposarcoma, Myxoid | 2 | 2007 | 38 | 0.190 |
Why?
|
| Stromal Cells | 3 | 2004 | 823 | 0.190 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2016 | 624 | 0.190 |
Why?
|
| Continuity of Patient Care | 1 | 2003 | 206 | 0.190 |
Why?
|
| Drug Repositioning | 1 | 2021 | 52 | 0.180 |
Why?
|
| Mutation | 10 | 2023 | 15904 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 3 | 2022 | 1388 | 0.180 |
Why?
|
| Joint Instability | 2 | 2011 | 78 | 0.180 |
Why?
|
| Skull Base Neoplasms | 1 | 2024 | 339 | 0.170 |
Why?
|
| Recurrence | 6 | 2017 | 4880 | 0.170 |
Why?
|
| Histiocytoma, Benign Fibrous | 3 | 2001 | 74 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2021 | 694 | 0.170 |
Why?
|
| Taxoids | 3 | 2012 | 1019 | 0.170 |
Why?
|
| Meta-Analysis as Topic | 2 | 2012 | 274 | 0.170 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2019 | 17 | 0.170 |
Why?
|
| Colitis | 1 | 2022 | 340 | 0.160 |
Why?
|
| Biomarkers, Tumor | 8 | 2024 | 10714 | 0.150 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2015 | 368 | 0.150 |
Why?
|
| Patient Compliance | 2 | 2013 | 678 | 0.150 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2015 | 677 | 0.150 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2000 | 402 | 0.150 |
Why?
|
| Fatal Outcome | 2 | 2016 | 821 | 0.150 |
Why?
|
| Outpatients | 2 | 2019 | 463 | 0.150 |
Why?
|
| Carbamates | 1 | 1998 | 81 | 0.150 |
Why?
|
| Genomics | 4 | 2023 | 2832 | 0.150 |
Why?
|
| Confidence Intervals | 2 | 2017 | 748 | 0.150 |
Why?
|
| Brugada Syndrome | 1 | 2017 | 20 | 0.140 |
Why?
|
| Patient Participation | 1 | 2021 | 454 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2017 | 7786 | 0.140 |
Why?
|
| Gastric Fundus | 1 | 2017 | 19 | 0.140 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 682 | 0.140 |
Why?
|
| Cisplatin | 6 | 2012 | 2499 | 0.140 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2017 | 78 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2004 | 770 | 0.140 |
Why?
|
| Consensus | 5 | 2022 | 1112 | 0.140 |
Why?
|
| Bone Cysts, Aneurysmal | 1 | 2016 | 20 | 0.140 |
Why?
|
| Time Factors | 12 | 2021 | 12990 | 0.140 |
Why?
|
| Osteoma, Osteoid | 1 | 2016 | 24 | 0.140 |
Why?
|
| Radiotherapy | 3 | 2019 | 1858 | 0.140 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2017 | 617 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2014 | 2663 | 0.140 |
Why?
|
| Retinal Vein Occlusion | 1 | 2016 | 29 | 0.130 |
Why?
|
| Age Factors | 7 | 2021 | 5458 | 0.130 |
Why?
|
| Cohort Studies | 12 | 2022 | 9478 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2003 | 898 | 0.130 |
Why?
|
| DNA Repair | 1 | 2024 | 1906 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2018 | 477 | 0.130 |
Why?
|
| Pneumonia | 1 | 2022 | 794 | 0.130 |
Why?
|
| Proteome | 1 | 2020 | 570 | 0.130 |
Why?
|
| Gene Fusion | 2 | 2015 | 214 | 0.130 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 521 | 0.130 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2015 | 23 | 0.130 |
Why?
|
| Radiography, Abdominal | 1 | 2016 | 126 | 0.130 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2015 | 562 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 359 | 0.130 |
Why?
|
| Pyrazoles | 2 | 2021 | 1550 | 0.130 |
Why?
|
| Mesenchymoma | 1 | 2015 | 14 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2017 | 381 | 0.130 |
Why?
|
| Fever | 3 | 2009 | 521 | 0.130 |
Why?
|
| Vincristine | 2 | 2017 | 1582 | 0.120 |
Why?
|
| Thrombocytopenia | 5 | 2020 | 871 | 0.120 |
Why?
|
| Giant Cell Tumors | 1 | 2015 | 33 | 0.120 |
Why?
|
| Peritoneal Neoplasms | 2 | 2000 | 863 | 0.120 |
Why?
|
| Torso | 1 | 2015 | 75 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2022 | 2359 | 0.120 |
Why?
|
| Dysgerminoma | 2 | 1992 | 42 | 0.120 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 247 | 0.120 |
Why?
|
| Heart | 1 | 2021 | 1172 | 0.120 |
Why?
|
| Pyrazines | 1 | 1998 | 511 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 266 | 0.120 |
Why?
|
| Patient Selection | 3 | 2017 | 2032 | 0.120 |
Why?
|
| Mass Screening | 1 | 2003 | 1554 | 0.120 |
Why?
|
| Spleen | 1 | 2017 | 721 | 0.120 |
Why?
|
| Proportional Hazards Models | 8 | 2019 | 5102 | 0.120 |
Why?
|
| Immunotherapy | 5 | 2022 | 3559 | 0.120 |
Why?
|
| Abdominal Neoplasms | 1 | 2016 | 251 | 0.120 |
Why?
|
| Osteotomy | 1 | 2015 | 106 | 0.120 |
Why?
|
| Gardner Syndrome | 1 | 1994 | 6 | 0.120 |
Why?
|
| Fibromatosis, Abdominal | 1 | 1994 | 9 | 0.120 |
Why?
|
| Inpatients | 1 | 2019 | 687 | 0.120 |
Why?
|
| Treatment Failure | 6 | 2017 | 1430 | 0.110 |
Why?
|
| Orthopedic Procedures | 2 | 2019 | 149 | 0.110 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2018 | 510 | 0.110 |
Why?
|
| Endocrine System Diseases | 1 | 2014 | 89 | 0.110 |
Why?
|
| Endpoint Determination | 1 | 2014 | 180 | 0.110 |
Why?
|
| Administration, Oral | 4 | 2009 | 1606 | 0.110 |
Why?
|
| Polyethylene Glycols | 2 | 2021 | 654 | 0.110 |
Why?
|
| Compassionate Use Trials | 1 | 2013 | 16 | 0.110 |
Why?
|
| Delphi Technique | 2 | 2014 | 279 | 0.110 |
Why?
|
| Pilot Projects | 5 | 2022 | 2853 | 0.110 |
Why?
|
| Orchiectomy | 2 | 1990 | 211 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 4052 | 0.110 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2012 | 66 | 0.100 |
Why?
|
| Spine | 2 | 2011 | 311 | 0.100 |
Why?
|
| Multivariate Analysis | 7 | 2021 | 4326 | 0.100 |
Why?
|
| Precision Medicine | 2 | 2017 | 1210 | 0.100 |
Why?
|
| Patient Safety | 1 | 2017 | 611 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2014 | 420 | 0.100 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 754 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2014 | 417 | 0.100 |
Why?
|
| Pineal Gland | 1 | 1992 | 43 | 0.100 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2011 | 30 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2010 | 741 | 0.100 |
Why?
|
| Bayes Theorem | 5 | 2016 | 1060 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2015 | 1260 | 0.100 |
Why?
|
| Research Design | 2 | 2014 | 1570 | 0.100 |
Why?
|
| Neoplasm Grading | 4 | 2018 | 1824 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2014 | 545 | 0.090 |
Why?
|
| Bisbenzimidazole | 1 | 1991 | 8 | 0.090 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2012 | 98 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 603 | 0.090 |
Why?
|
| Paclitaxel | 2 | 2001 | 2105 | 0.090 |
Why?
|
| Electrocardiography | 1 | 2017 | 1147 | 0.090 |
Why?
|
| Radiotherapy Dosage | 6 | 2007 | 4020 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 3 | 2008 | 565 | 0.090 |
Why?
|
| Immunologic Factors | 3 | 2000 | 670 | 0.090 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2011 | 49 | 0.090 |
Why?
|
| Hemangiopericytoma | 1 | 2011 | 59 | 0.090 |
Why?
|
| Kidney Neoplasms | 2 | 2017 | 3109 | 0.090 |
Why?
|
| Megestrol | 1 | 1990 | 15 | 0.090 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2010 | 28 | 0.090 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 550 | 0.090 |
Why?
|
| Remission Induction | 8 | 1997 | 3657 | 0.090 |
Why?
|
| Brain Neoplasms | 2 | 2022 | 4966 | 0.090 |
Why?
|
| International Agencies | 1 | 2010 | 108 | 0.090 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2010 | 70 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2014 | 2357 | 0.090 |
Why?
|
| Liver Neoplasms | 3 | 2012 | 4826 | 0.090 |
Why?
|
| Thrombopoietin | 2 | 2003 | 102 | 0.090 |
Why?
|
| Breast Neoplasms | 5 | 2021 | 16238 | 0.090 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1994 | 407 | 0.090 |
Why?
|
| Surgeons | 1 | 2016 | 494 | 0.090 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 1341 | 0.090 |
Why?
|
| Animals | 9 | 2021 | 61554 | 0.090 |
Why?
|
| Cyclophosphamide | 4 | 2003 | 3244 | 0.080 |
Why?
|
| Drugs, Investigational | 1 | 2011 | 130 | 0.080 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2015 | 881 | 0.080 |
Why?
|
| Advisory Committees | 1 | 2010 | 196 | 0.080 |
Why?
|
| Humerus | 1 | 2009 | 53 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 3 | 2011 | 4148 | 0.080 |
Why?
|
| Stomatitis | 1 | 2010 | 193 | 0.080 |
Why?
|
| Aza Compounds | 1 | 2009 | 25 | 0.080 |
Why?
|
| Fluoroquinolones | 2 | 2009 | 135 | 0.080 |
Why?
|
| Europe | 2 | 2021 | 658 | 0.080 |
Why?
|
| Lung Neoplasms | 8 | 2016 | 12040 | 0.080 |
Why?
|
| Octreotide | 1 | 1989 | 132 | 0.080 |
Why?
|
| Child, Preschool | 14 | 2020 | 17095 | 0.080 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 1995 | 425 | 0.080 |
Why?
|
| Alanine Transaminase | 2 | 2020 | 238 | 0.080 |
Why?
|
| Quality of Life | 1 | 2022 | 4794 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2010 | 557 | 0.080 |
Why?
|
| Double-Blind Method | 4 | 2019 | 2582 | 0.070 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 2198 | 0.070 |
Why?
|
| Global Health | 1 | 2013 | 691 | 0.070 |
Why?
|
| Injections, Intravenous | 2 | 2006 | 591 | 0.070 |
Why?
|
| Immunohistochemistry | 7 | 2019 | 7645 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2017 | 2658 | 0.070 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1990 | 346 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2011 | 959 | 0.070 |
Why?
|
| Radiography | 5 | 2013 | 1993 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2019 | 2272 | 0.070 |
Why?
|
| Leukopenia | 3 | 2017 | 152 | 0.070 |
Why?
|
| United States | 3 | 2020 | 15889 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 2453 | 0.070 |
Why?
|
| Thiazines | 1 | 2005 | 3 | 0.070 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2013 | 1235 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2001 | 898 | 0.070 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1991 | 690 | 0.070 |
Why?
|
| Retreatment | 2 | 2017 | 449 | 0.060 |
Why?
|
| Bone Marrow Diseases | 3 | 1997 | 186 | 0.060 |
Why?
|
| Infusions, Intra-Arterial | 3 | 2002 | 174 | 0.060 |
Why?
|
| Prospective Studies | 5 | 2022 | 13445 | 0.060 |
Why?
|
| Quinolines | 1 | 2009 | 402 | 0.060 |
Why?
|
| Constipation | 1 | 2006 | 189 | 0.060 |
Why?
|
| Ovarian Neoplasms | 2 | 2021 | 4796 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 1036 | 0.060 |
Why?
|
| Fatigue | 2 | 2014 | 1281 | 0.060 |
Why?
|
| Feasibility Studies | 4 | 2009 | 2364 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2018 | 5417 | 0.060 |
Why?
|
| Medical Records | 3 | 2017 | 442 | 0.060 |
Why?
|
| Dexamethasone | 1 | 1990 | 1516 | 0.060 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 466 | 0.060 |
Why?
|
| Biopsy, Needle | 3 | 2019 | 1382 | 0.060 |
Why?
|
| Interleukin-3 | 2 | 1995 | 106 | 0.060 |
Why?
|
| Diagnostic Imaging | 2 | 2022 | 1173 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2004 | 1363 | 0.060 |
Why?
|
| Acute Disease | 1 | 2009 | 2492 | 0.060 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2005 | 142 | 0.060 |
Why?
|
| Regression Analysis | 4 | 2010 | 1567 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2016 | 6191 | 0.050 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2003 | 73 | 0.050 |
Why?
|
| Disease Management | 2 | 2019 | 1092 | 0.050 |
Why?
|
| Etoposide | 2 | 2012 | 907 | 0.050 |
Why?
|
| Tumor Burden | 3 | 2015 | 2033 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2002 | 125 | 0.050 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 5165 | 0.050 |
Why?
|
| Mutation, Missense | 2 | 2005 | 1197 | 0.050 |
Why?
|
| Observer Variation | 2 | 2016 | 710 | 0.050 |
Why?
|
| Spermatic Cord | 1 | 2001 | 18 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 2403 | 0.050 |
Why?
|
| Intraoperative Care | 1 | 2003 | 273 | 0.050 |
Why?
|
| Carcinoma | 2 | 1992 | 2610 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2003 | 199 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2003 | 456 | 0.050 |
Why?
|
| Genital Neoplasms, Male | 1 | 2001 | 44 | 0.050 |
Why?
|
| Thiazoles | 1 | 2005 | 727 | 0.050 |
Why?
|
| Connective Tissue | 1 | 2021 | 36 | 0.050 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2021 | 43 | 0.050 |
Why?
|
| Asia | 1 | 2021 | 155 | 0.050 |
Why?
|
| Thoracic Neoplasms | 1 | 2024 | 363 | 0.050 |
Why?
|
| Professional Staff Committees | 1 | 2001 | 30 | 0.050 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2001 | 73 | 0.050 |
Why?
|
| Australia | 1 | 2021 | 259 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 7320 | 0.050 |
Why?
|
| Health Records, Personal | 1 | 2020 | 21 | 0.050 |
Why?
|
| Texas | 5 | 2016 | 6452 | 0.050 |
Why?
|
| Phosphates | 1 | 2001 | 178 | 0.050 |
Why?
|
| North America | 1 | 2021 | 341 | 0.050 |
Why?
|
| Drug Evaluation | 2 | 1991 | 432 | 0.040 |
Why?
|
| Immunogenetic Phenomena | 1 | 2020 | 9 | 0.040 |
Why?
|
| Latin America | 1 | 2020 | 127 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2023 | 605 | 0.040 |
Why?
|
| Incidence | 3 | 2021 | 5841 | 0.040 |
Why?
|
| Mesna | 2 | 1997 | 67 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2021 | 152 | 0.040 |
Why?
|
| Recombinant Proteins | 5 | 2011 | 2990 | 0.040 |
Why?
|
| Reoperation | 2 | 2003 | 1394 | 0.040 |
Why?
|
| Anemia | 2 | 2017 | 727 | 0.040 |
Why?
|
| Injections, Subcutaneous | 4 | 1995 | 342 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 1310 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2022 | 440 | 0.040 |
Why?
|
| Patient Care | 1 | 2020 | 148 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 705 | 0.040 |
Why?
|
| Prostatic Neoplasms | 3 | 1992 | 5867 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1995 | 1630 | 0.040 |
Why?
|
| Mastectomy | 1 | 2005 | 1553 | 0.040 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2000 | 182 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2023 | 522 | 0.040 |
Why?
|
| Analysis of Variance | 4 | 2004 | 2317 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2021 | 544 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2022 | 889 | 0.040 |
Why?
|
| Biomarkers | 2 | 2023 | 5054 | 0.040 |
Why?
|
| beta Catenin | 1 | 2022 | 689 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2001 | 709 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2019 | 6779 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2018 | 87 | 0.040 |
Why?
|
| Succinate Dehydrogenase | 1 | 2018 | 48 | 0.040 |
Why?
|
| Quinazolines | 1 | 2023 | 956 | 0.040 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2018 | 106 | 0.040 |
Why?
|
| Hematopoiesis | 3 | 1997 | 600 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 367 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 1421 | 0.040 |
Why?
|
| Cardiac Conduction System Disease | 1 | 2017 | 16 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 559 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 726 | 0.040 |
Why?
|
| Neoplasms | 3 | 2016 | 15933 | 0.040 |
Why?
|
| American Cancer Society | 1 | 2017 | 35 | 0.040 |
Why?
|
| Arm | 1 | 1997 | 139 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2017 | 146 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2010 | 2882 | 0.030 |
Why?
|
| Heart Failure | 1 | 2010 | 2321 | 0.030 |
Why?
|
| Bone Marrow | 4 | 2003 | 2440 | 0.030 |
Why?
|
| Megakaryocytes | 1 | 1997 | 128 | 0.030 |
Why?
|
| Lymphatic Metastasis | 4 | 2012 | 4969 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1997 | 472 | 0.030 |
Why?
|
| DNA Damage | 1 | 2024 | 1990 | 0.030 |
Why?
|
| Translocation, Genetic | 2 | 2014 | 1286 | 0.030 |
Why?
|
| Exons | 2 | 2014 | 1390 | 0.030 |
Why?
|
| Doxycycline | 1 | 2016 | 179 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 1095 | 0.030 |
Why?
|
| Radiation Oncology | 1 | 2001 | 558 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2018 | 487 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 4966 | 0.030 |
Why?
|
| Radiology, Interventional | 1 | 2016 | 142 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2021 | 1572 | 0.030 |
Why?
|
| Registries | 2 | 2015 | 2221 | 0.030 |
Why?
|
| Infant | 6 | 2010 | 14045 | 0.030 |
Why?
|
| Piperidines | 1 | 2020 | 1099 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1995 | 198 | 0.030 |
Why?
|
| Diphosphonates | 1 | 2016 | 264 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 5938 | 0.030 |
Why?
|
| Denosumab | 1 | 2015 | 72 | 0.030 |
Why?
|
| Breast | 1 | 2021 | 1369 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2019 | 1420 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2016 | 454 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 1135 | 0.030 |
Why?
|
| Mitotic Index | 1 | 2014 | 162 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2001 | 5581 | 0.030 |
Why?
|
| Methotrexate | 2 | 1995 | 1025 | 0.030 |
Why?
|
| Muscular Diseases | 1 | 1994 | 157 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 879 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 3197 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 1991 | 5263 | 0.030 |
Why?
|
| Apoptosis | 1 | 2007 | 7755 | 0.030 |
Why?
|
| Ambulatory Care | 2 | 2009 | 592 | 0.030 |
Why?
|
| Thigh | 1 | 1994 | 165 | 0.030 |
Why?
|
| Vinblastine | 1 | 1993 | 462 | 0.030 |
Why?
|
| Urinary Bladder Diseases | 1 | 1993 | 53 | 0.030 |
Why?
|
| Blood Platelets | 1 | 1997 | 676 | 0.030 |
Why?
|
| Dogs | 1 | 2014 | 1074 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2000 | 1715 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 1581 | 0.030 |
Why?
|
| Sirolimus | 1 | 2016 | 830 | 0.020 |
Why?
|
| Actuarial Analysis | 2 | 2001 | 170 | 0.020 |
Why?
|
| Nausea | 1 | 2014 | 539 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2012 | 231 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 1997 | 2344 | 0.020 |
Why?
|
| Chromaffin System | 1 | 2010 | 8 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 3657 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3041 | 0.020 |
Why?
|
| Mitomycin | 1 | 1992 | 213 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 1996 | 797 | 0.020 |
Why?
|
| Megestrol Acetate | 1 | 1990 | 30 | 0.020 |
Why?
|
| Maintenance Chemotherapy | 1 | 2012 | 226 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 2 | 1997 | 616 | 0.020 |
Why?
|
| Survival | 1 | 2010 | 183 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2015 | 1022 | 0.020 |
Why?
|
| Thoracic Vertebrae | 1 | 2011 | 200 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 451 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2011 | 219 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2011 | 247 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2000 | 7899 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2010 | 224 | 0.020 |
Why?
|
| Pedigree | 1 | 1994 | 2041 | 0.020 |
Why?
|
| Heat-Shock Response | 1 | 2009 | 40 | 0.020 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 3345 | 0.020 |
Why?
|
| Proteomics | 1 | 2016 | 1425 | 0.020 |
Why?
|
| Fibrosarcoma | 1 | 2009 | 143 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2017 | 12044 | 0.020 |
Why?
|
| Forecasting | 2 | 2002 | 702 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 1303 | 0.020 |
Why?
|
| Induction Chemotherapy | 1 | 2012 | 670 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 986 | 0.020 |
Why?
|
| Muscles | 1 | 2009 | 443 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 1991 | 337 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4503 | 0.020 |
Why?
|
| Carboplatin | 1 | 2001 | 880 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 2220 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 3472 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2011 | 1171 | 0.020 |
Why?
|
| Fluorouracil | 1 | 1992 | 1990 | 0.020 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 376 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2002 | 968 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 4838 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2007 | 223 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2011 | 967 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 1990 | 566 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2011 | 1273 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2011 | 1020 | 0.020 |
Why?
|
| Fibrosis | 2 | 2001 | 716 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 831 | 0.020 |
Why?
|
| Testis | 1 | 1989 | 620 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2010 | 5662 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2007 | 757 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 1552 | 0.020 |
Why?
|
| Osteitis | 1 | 2005 | 16 | 0.020 |
Why?
|
| Norway | 1 | 2005 | 42 | 0.020 |
Why?
|
| Demography | 1 | 2006 | 434 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 3110 | 0.020 |
Why?
|
| Hyperparathyroidism | 1 | 2005 | 101 | 0.010 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 511 | 0.010 |
Why?
|
| Laparoscopy | 1 | 1994 | 1304 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2010 | 696 | 0.010 |
Why?
|
| Base Sequence | 2 | 2004 | 5417 | 0.010 |
Why?
|
| Linear Models | 1 | 2007 | 1095 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 9044 | 0.010 |
Why?
|
| Cancer Care Facilities | 1 | 2009 | 907 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 887 | 0.010 |
Why?
|
| Echocardiography | 1 | 2010 | 1219 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 1176 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 453 | 0.010 |
Why?
|
| Necrosis | 1 | 2004 | 593 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 6503 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 1900 | 0.010 |
Why?
|
| Biopsy | 1 | 2009 | 3488 | 0.010 |
Why?
|
| Decision Trees | 1 | 2002 | 181 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 1469 | 0.010 |
Why?
|
| Trastuzumab | 1 | 2003 | 743 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 5775 | 0.010 |
Why?
|
| Blotting, Western | 2 | 1996 | 3570 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2010 | 4105 | 0.010 |
Why?
|
| Morbidity | 1 | 2000 | 400 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2001 | 477 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 5143 | 0.010 |
Why?
|
| Capillary Leak Syndrome | 1 | 1997 | 12 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 2597 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 1996 | 5759 | 0.010 |
Why?
|
| Respiration Disorders | 1 | 1997 | 48 | 0.010 |
Why?
|
| Femoral Neoplasms | 1 | 1997 | 67 | 0.010 |
Why?
|
| Prevalence | 1 | 2005 | 3412 | 0.010 |
Why?
|
| Alopecia | 1 | 1997 | 125 | 0.010 |
Why?
|
| Ploidies | 1 | 1997 | 250 | 0.010 |
Why?
|
| Transcription Factor AP-2 | 1 | 1996 | 78 | 0.010 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1996 | 71 | 0.010 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 1996 | 50 | 0.010 |
Why?
|
| Platelet Count | 1 | 1997 | 490 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1995 | 83 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1996 | 275 | 0.010 |
Why?
|
| Hypotension | 1 | 1997 | 227 | 0.010 |
Why?
|
| Growth Substances | 1 | 1996 | 325 | 0.010 |
Why?
|
| Chromosome Inversion | 1 | 1996 | 197 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1995 | 7273 | 0.010 |
Why?
|
| Premedication | 1 | 1995 | 133 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1995 | 253 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1995 | 233 | 0.010 |
Why?
|
| Survivors | 1 | 2001 | 1021 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 1942 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 14873 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1995 | 385 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 1408 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1997 | 1355 | 0.010 |
Why?
|
| Antibodies | 1 | 1997 | 806 | 0.010 |
Why?
|
| Safety | 1 | 1995 | 460 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2001 | 1475 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 1995 | 675 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 1999 | 1761 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 1127 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 1992 | 56 | 0.010 |
Why?
|
| Melanoma | 1 | 1989 | 5597 | 0.010 |
Why?
|
| Acetylcysteine | 1 | 1993 | 133 | 0.010 |
Why?
|
| Fluid Therapy | 1 | 1993 | 194 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 1996 | 862 | 0.010 |
Why?
|
| Neutrophils | 1 | 1995 | 855 | 0.010 |
Why?
|
| Cell Survival | 1 | 1996 | 3058 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1996 | 4542 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 2002 | 2338 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1995 | 2135 | 0.010 |
Why?
|
| Cell Division | 1 | 1994 | 2657 | 0.010 |
Why?
|
| Ovariectomy | 1 | 1990 | 372 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 6655 | 0.010 |
Why?
|
| Laparotomy | 1 | 1990 | 249 | 0.010 |
Why?
|
| Cytokines | 1 | 1997 | 2805 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 3330 | 0.000 |
Why?
|
| Abdominal Pain | 1 | 1990 | 378 | 0.000 |
Why?
|
| Hysterectomy | 1 | 1990 | 654 | 0.000 |
Why?
|
| Lung | 1 | 1996 | 3288 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 2000 | 5679 | 0.000 |
Why?
|
| Nuclear Proteins | 1 | 1995 | 3435 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 1996 | 4994 | 0.000 |
Why?
|
| Transcription Factors | 1 | 1996 | 5416 | 0.000 |
Why?
|